Methods of treating melanoma using tebentafusp and immune checkpoint inhibitors

A method of treating melanoma in a patient, comprising:

• administering to a patient who is refractory to or relapsed following a prior checkpoint inhibitor treatment:
• a therapeutically effective amount of tebentafusp;
• and
• a therapeutically effective amount of a first immune checkpoint inhibitor.

A method of treating metastatic cutaneous melanoma in a patient, comprising:

• administering:
• tebentafusp at a dose ranging from about 10 mcg to about 68 mcg;
• and
• a PD(L)1 inhibitor at a therapeutically effective amount,
• wherein the tebentafusp is administered about once weekly,
• wherein the PD(L)1 inhibitor is administered about once every four weeks, and
• wherein the PD(L)1 inhibitor is first administered about 15 days after the first administration of the tebentafusp.

A method of treating metastatic cutaneous melanoma in a patient, comprising:

• administering:
• tebentafusp at a dose ranging from about 10 mcg to about 68 mcg;
• and
• durvalumab at a dose ranging from about 1 mg/kg to about 20 mg/kg,
• wherein the tebentafusp is administered about once weekly,
• wherein the durvalumab is administered about once every four weeks, and
• wherein the durvalumab is first administered about 15 days after the first administration of the tebentafusp.

A method of treating metastatic cutaneous melanoma in a patient, comprising:

• administering:
• tebentafusp at a dose ranging from about 10 mcg to about 50 mcg;
• and
• a CTLA-4 inhibitor at a therapeutically effective amount,
• wherein the tebentafusp is administered about once weekly,
• wherein the CTLA-4 inhibitor is administered about once every four weeks, and
• wherein the CTLA-4 inhibitor is first administered about 15 days after the first administration of the tebentafusp.

A method of treating metastatic cutaneous melanoma in a patient, comprising:

• administering:
• tebentafusp at a dose ranging from about 10 mcg to about 50 mcg;
• and
• tremelimumab at a dose ranging from about 0.5 mg/kg to about 10 mg/kg,
• wherein the tebentafusp is administered about once weekly,
• wherein the tremelimumab is administered about once every four weeks, and
• wherein the tremelimumab is first administered about 15 days after the first administration of the tebentafusp.

A method of treating metastatic cutaneous melanoma in a patient, comprising:

• administering:
• tebentafusp at a dose ranging from about 10 mcg to about 50 mcg;
• a PD(L)1 inhibitor at a therapeutically effective amount;
• and
• a CTLA-4 inhibitor at a therapeutically effective amount,
• wherein the tebentafusp is administered about once weekly,
• wherein the PD(L)1 inhibitor is administered about once every four weeks,
• wherein the CTLA-4 inhibitor is administered about once every four weeks, and
• wherein the PD(L)1 inhibitor and the CTLA-4 inhibitor are first administered about 15 days after the first administration of the tebentafusp.

A method of treating metastatic cutaneous melanoma in a patient, comprising:

• administering:
• tebentafusp at a dose ranging from about 10 mcg to about 68 mcg;
• durvalumab at a dose ranging from about 1 mg/kg to about 20 mg/kg;
• and
• tremelimumab at a dose ranging from about 0.5 mg/kg to about 10 mg/kg,
• wherein the tebentafusp is administered about once weekly,
• wherein the durvalumab is administered about once every four weeks,
• wherein the tremelimumab is administered about once every four weeks, and
• wherein the durvalumab and the tremelimumab are first administered about 15 days after the first administration of the tebentafusp.